Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

More documents

Recommendations

Info

Abbreviations Abbreviations ACN CD CRTT EMEA GCP GMP HPβCD HPγCD HPLC i.m. i.v. ICH ISI LC-MS MRI MWCO Ph.Eur. RMβCD RT SD VAS Acetonitril Cyclodextrin Computer-controlled self-adjusting reaction time test European Agency for the Evaluation of Medicinal Products Good Clinical Practice Good Manufacturing Practice Hydroxypropyl-β-Cyclodextrin Hydroxypropyl-γ-Cyclodextrin High Performance Liquid Chromatography intramuscular intravenous International Conference on the Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use Interstimulus Interval Liquid chromatography-mass spectrometry Magnetic Resonance Imaging Molecular Weight Cut Off Pharmacopoeia Europaea Randomized methylated-β-cyclodextrin Reaction Time Standard Deviation Visual Analog Scale Katja Suter-Zimmermann Page 1 of 188 University of Basel, 2008
Page 1: TRANSMUCOSAL NASAL DRUG DELIVERY Sy
Page 5 and 6: Acknowledgments At the Hospital Pha
Page 7: Index EXPERIMENTAL SECTION 5 Projec
Page 12 and 13: Summary Project II: Pharmacokinetic
Page 15: Background and objectives Backgroun
Page 19 and 20: 1. Nasal drug delivery 1 Nasal drug
Page 21 and 22: 1. Nasal drug delivery Table 1-1: C
Page 23: 1. Nasal drug delivery 1.4 Nose to
Page 26 and 27: 2. Impact of anatomy and physiology
Page 32 and 33: 3. Midazolam 3.2 Pharmacologic effe
Page 34 and 35: 3. Midazolam 3.2.2 Conscious sedati
Page 36 and 37: 3. Midazolam Table 3-2: Benefits an
Page 38 and 39: 3. Midazolam Table 3-4: Indications
Page 40 and 41: 4. Compounding of nasal midazolam p
Page 51: EXPERIMENTAL SECTION
Page 54 and 55: 5. Project I: Development of prepar
Page 56 and 57: 5. Project I: Development of prepar
Page 58 and 59:
5. Project I: Development of prepar
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 69 and 70:
6. Project II: Pharmacokinetic of t
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89:
Page 92 and 93:
7. Project III: Transmucosal nasal
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 105 and 106:
8 Overall discussion 8 Overall disc
Page 107 and 108:
8 Overall discussion unusual applic
Page 109:
8 Overall discussion 9 Final conclu
Page 113 and 114:
10 Appendix 10.1.1 Pharmacokinetic
Page 115 and 116:
10 Appendix 10.2.3 Accelerated stab
Page 117 and 118:
10 Appendix 10.2.5 Specification: M
Page 119 and 120:
10 Appendix 10.2.7 Specification: C
Page 121 and 122:
10 Appendix 10.2.8 Specification: C
Page 123 and 124:
10 Appendix 10.2.10 Stability repor
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
10 Appendix Project II 10.3.1 Study
Page 137 and 138:
10 Appendix Katja Suter-Zimmermann
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
10 Appendix 1.3.3 Case report form:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
10 Appendix Frequency 10.3.6 Intens
Page 161 and 162:
10 Appendix Identification midazola
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
10 Appendix 10.3.9 Nasal delivery o
Page 171 and 172:
10 Appendix 10.4. Project III 10.4.
Page 173 and 174:
Page 175 and 176:
10 Appendix 10.4.4 Instruction mate
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183:
Page 186 and 187:
11 References Cote, C.J., Md, I.T.
Page 188 and 189:
11 References Griffith, N., S. Howe
Page 190 and 191:
11 References Lahat, E., M. Goldman
Page 192 and 193:
11 References Mygind, N. and R. Dah
Page 194 and 195:
11 References Tschirch, F.T., K. Go
Page 196:
12 Curriculum vitae During my acade
show all

Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

Create successful ePaper yourself

Delete template?

Save as template?